Skip to main content

COMPASS Pathways plc

corporate_fare Company Profile

COMPASS Pathways plc

CMPS·NASDAQ·Life Sciences·CIK 0001816590

COMPASS Pathways plc is a biotechnology company focused on developing innovative treatments for mental health conditions. The company is developing COMP360 psilocybin treatment, a proprietary formulation of pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. This investigational treatment aims to provide rapid and durable responses for serious mental health conditions, including treatment-resistant depression (TRD), a subset of major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The initial focus is on TRD, addressing patients not adequately served by current treatments. In 2018, COMPASS Pathways received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for COMP360 for TRD. In November 2021, the company announced positive top-line results from its Phase 2b clinical trial evaluating COMP360 for TRD. These results were published in The New England Journal of Medicine on November 3, 2022. This Phase 2b study, the largest randomized, controlled, double-blind psilocybin treatment clinical trial completed to date, evaluated the efficacy and safety of a single dose of COMP360 (25mg or 10mg) compared to 1mg in TRD patients. The trial met its primary endpoint for the 25mg dose, showing a statistically significant and clinically relevant reduction in depressive symptom severity after three weeks against the 1mg dose. In 2025, the company completed enrollment for both pivotal trials in its Phase 3 program for COMP360 in TRD, each including a long-term follow-up component.

COMPASS Pathways plc (NASDAQ:CMPS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CMPS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • COMPASS Pathways Secures Up To $150M Debt Facility for Clinical Development

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$287.86M
Diluted EPS
-$3.08
Op. Cash Flow
-$157.24M
Operating Income
-$179.04M
Cash & Equivalents
$149.61M
Total Debt
$31.63M
Debt / Equity
-0.60×
Shares Outstanding
96.09M sh
Source: 10-K · filed 2026-03-24 · accession 0001816590-26-000020
$8.2 +1.86% today
52-week range · as of 2026-11-03 $4.88 – $15.87
Market cap
$1.14B
Volume
6.1M (1.7× avg)
3-mo avg 3.5M
Live data · 2026-11-21 16:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CMPS - Filings & News (Page 2)

CMPS
Jan 07, 2026, 6:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.23
Real-time Price: $8.20 info
Change: +$0.970 (+13%) info
Market Cap: $1.141B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets